Opko Health, Inc. (NASDAQ:OPK)
OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.
Opko Health, Inc. (NASDAQ:OPK)’s Financial Overview
Opko Health, Inc. (NASDAQ) surged 3.28% yesterday to close its trading session at $2.83. The company has 1 year Price Target of $10. Opko Health, Inc. has 52-Week high of $6.4 and 52-Week Low of $2.34. The stock touched its 52-Week High on 6.40 and 52-Week Low on 2.34. The stock traded with the volume of 5.73 Million shares yesterday. The firm shows the market capitalization of $1.7 Billion.
Opko Health, Inc. (NASDAQ) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $-0.05/share against the analyst consensus estimate of $-0.08/share. The difference between the actual and expected EPS is $0.03 a share with a surprise factor of 37.5%.
The firm is trading with SMA20 of -18.04 Percent, SMA50 of -15.27 Percent and SMA200 of -31.31 percent. Opko Health, Inc. has P/S value of 1.77 while its P/B value stands at 0.88. Similarly, the company has Return on Assets of -11.4 percent, Return on Equity of -16 percent and Return on Investment of -14.8 Percent. The company shows Gross Margin and Operating Margin of 36.4 percent and -24.4 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 2 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 3 analysts offering 12-month price forecasts for OPKO Health Inc have a median target of 7.00, with a high estimate of 19.00 and a low estimate of 4.00. The median estimate represents a +147.35% increase from the last price of 2.83.
Opko Health, Inc. is estimated to report earnings on 03/07/2019. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.09. The reported EPS for the same quarter last year was $-0.12.
Aflac Incorporated (NYSE:AFL)
Aflac, Inc. is a Fortune 500 company, providing financial protection to more than 50 million people worldwide. When a policyholder or insured gets sick or hurt, Aflac pays cash benefits fairly, promptly, and often in one day for eligible claims, directly to the insured (unless assigned otherwise). American Family Life pioneered the introduction of a cancer policy after identifying the need to lift the financial burden of cancer patients and their families. For more than six decades, Aflac voluntary insurance policies have given policyholders the opportunity to focus on recovery, not financial stress.
Aflac Incorporated (NYSE:AFL)’s Financial Outlook
The 14 analysts offering 12-month price forecasts for Aflac Inc have a median target of 47.50, with a high estimate of 53.00 and a low estimate of 40.00. The median estimate represents a -2.94% decrease from the last price of 48.94.
Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.
According to Zacks Investment Research, Aflac Incorporated has a Consensus Recommendation of 2.25. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock surged 1.39% and closed its last trading session at $48.94. The company has the market capitalization of $37.47 Billion. The stock has 52-week high of $49.07 and 52-Week low of $41.45. The firm touched its 52-Week high on 48.59 and 52-Week low on 41.45. The company has volume of 2.56 Million shares. The company has a total of 765.55 Million shares outstanding.
Aflac Incorporated (NYSE) in the last quarter reported its actual EPS of $1.02/share where the analyst estimated EPS was $0.94/share. The difference between the actual and Estimated EPS is $0.08. This shows a surprise factor of 8.5 percent.
The company has YTD performance of 7.42 percent. Beta for Aflac Incorporated stands at 0.77 while its ATR (average true range) is 0.73. The company has Weekly Volatility of 1.28%% and Monthly Volatility of 1.48%%.
Aflac Incorporated has distance from 20-day Simple Moving Average (SMA20) of 2.91%, Distance from 50-Day Simple Moving Average of 6.99 percent and Distance from 200-Day Simple Moving Average of 7.9%.
The Company currently has ROA (Return on Assets) of 3.4 percent, Return on Equity (ROE) of 20.2 Percent and Return on Investment (ROI) of 9.7% with Gross margin of 0 percent and Operating & Profit margin of 20.3% and 22.3% respectively.